Sarcopenia in gynaecological cancers.

Autor: Di Fiore R; Department of Anatomy, Faculty of Medicine and Surgery, University of Malta, MSD 2080, Msida, Malta; Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, 19122, USA. Electronic address: riccardo.difiore@um.edu.mt., Drago-Ferrante R; Department of Anatomy, Faculty of Medicine and Surgery, University of Malta, MSD 2080, Msida, Malta; BioDNA Laboratories, Malta Life Sciences Park, SGN 3000, San Gwann, Malta. Electronic address: rosa.dragoferrante@biodna.net., Suleiman S; Department of Anatomy, Faculty of Medicine and Surgery, University of Malta, MSD 2080, Msida, Malta. Electronic address: sherif.s.suleiman@um.edu.mt., Veronese N; Department of Internal Medicine, Geriatrics Section, University of Palermo, 90128, Palermo, Italy. Electronic address: nicola.veronese@unipa.it., Pegreffi F; Department of Medicine and Surgery, Kore University of Enna, 94100, Enna, Italy. Electronic address: francesco.pegreffi@unikore.it., Calleja-Agius J; Department of Anatomy, Faculty of Medicine and Surgery, University of Malta, MSD 2080, Msida, Malta. Electronic address: jean.calleja-agius@um.edu.mt.
Jazyk: angličtina
Zdroj: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology [Eur J Surg Oncol] 2024 May 08, pp. 108403. Date of Electronic Publication: 2024 May 08.
DOI: 10.1016/j.ejso.2024.108403
Abstrakt: Gynaecological cancers (GCs) comprise a group of cancers that originate in the female reproductive organs. Each GC is unique, with different signs and symptoms, risk factors and therapeutic strategies. Worldwide, the majority of GCs are still associated with high mortality rates, especially ovarian, due to difficulty in early detection. Despite numerous studies on the underlying pathophysiology, research in the field of GCs poses unique scientific and technological challenges. These challenges require a concerted multi- and inter-disciplinary effort by the clinical, scientific and research communities to accelerate the advancement of prognostic, diagnostic, and therapeutic approaches. Sarcopenia is a multifactorial disease which leads to the systemic loss of skeletal muscle mass and function. It can be caused by malignancies, as well as due to malnutrition, physical inactivity, ageing and neuromuscular, inflammatory, and/or endocrine diseases. Anorexia and systemic inflammation can shift the metabolic balance of patients with cancer cachexia towards catabolism of skeletal muscle, and hence sarcopenia. Therefore, sarcopenia is considered as an indicator of poor general health status, as well as the possible indicator of advanced cancer. There is a growing body of evidence showing the prognostic significance of sarcopenia in various cancers, including GCs. This review will outline the clinical importance of sarcopenia in patients with GCs.
Competing Interests: Declaration of competing interest None.
(© 2024 Elsevier Ltd, BASO ∼ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: